evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

24 questions · 24 findings · 1 reviews · ENT

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 4.2%GRADE not reported 0 · 0%Very low 8 · 33.3%Low 8 · 33.3%Moderate 5 · 20.8%High 2 · 8.3%

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Avoidance of surgery ‐ patients still meeting the criteria for surgery At end of · patients with severe chronic rhinosinusitis with nasal polyps

It is very uncertain whether anti‐IL‐5 mAb (mepolizumab) changes avoidance of surgery ‐ patients still meeting the criteria for… compared with placebo (on top of topical steroids) (very low certainty).

1 finding from 1 review

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐5 mAb (mepolizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an improvement in SNOT‐22 score of ≥ 8.9 points · patients with chronic rhinosinusitis with nasal polyps

Anti‐IgE mAb (omalizumab) may leads to higher avoidance of surgery Nasal polyp score ≤4 (≤ 2 on each side) and an… compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

Adverse events ‐ nasopharyngitis, including sore throat · patients with chronic rhinosinusitis with nasal polyps

Anti‐IgE mAb (omalizumab) showed no clear difference in adverse events ‐ nasopharyngitis, including sore throat compared with placebo (on top of topical steroids) (low certainty).

1 finding from 1 review

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

Avoidance of surgery ‐ number of patients who had surgery as rescue treatment · patients with severe chronic rhinosinusitis with nasal polyps

Anti‐IL‐4Rα mAb (dupilumab) probably leads to lower avoidance of surgery ‐ number of patients who had surgery as rescue… compared with placebo (on top of topical steroids) (moderate certainty).

1 finding from 1 review